Test description
Testing (next generation sequencing) for NTRK1, NTRK2, and NTRK3 fusions in tumour tissue, for patients with tumours that are at risk of being caused by NTRK gene fusions.
Test information
NTRK 1/2/3 Fusions
Testing for patients with a tumour at risk of NTRK fusion determined by occurring in a child less than 18 years of age, or being mammary analogue secretory carcinoma of the salivary gland, or being secretory breast carcinoma. Information from this test may assist in determining suitability for treatment with targeted therapies (tropomyosin receptor kinase inhibitors).
NTRK 1/2/3
NGS Oncomine Precision Assay
1 week from receipt of sample
73433 criteria apply
If not MBS eligible. Please contact 1800 822 999 for pricing details
Standard pathology request form
FFPE Tumour Tissue
N/A
6 x 5 micron slides plus 1 x H&E stained slide required